Genetic screening and diagnosis in epilepsy?

Current Opinion in Neurology

Volumn 28, Issue 2, 2015, Pages 136-142

  Sisodiya, Sanjay M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Diagnostic; Epilepsy; Genetics; Sequencing; Testing

Indexed keywords

BENZODIAZEPINE DERIVATIVE; VALPROIC ACID;

ARRAY COMPARATIVE GENOMIC HYBRIDIZATION; CLINICAL PRACTICE; COMPARATIVE GENOMIC HYBRIDIZATION; EPILEPSY; EXOME; GENE EXPRESSION; GENETIC SCREENING; GENOME; GENOTYPE PHENOTYPE CORRELATION; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NEXT GENERATION SEQUENCING; REVIEW; WHOLE EXOME SEQUENCING; WHOLE GENOME SEQUENCING; ANIMAL; GENE THERAPY; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENETICS; HUMAN;

ANIMALS; EPILEPSY; EXOME; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENETIC THERAPY; GENETIC VARIATION; HUMANS;

EID: 84926336930     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000180     Document Type: Review

References (53)

1. Allen AS, Berkovic SF, Cossette F, et al., Epi4K Consortium; Epilepsy Phenome/Genome Project. De novo mutations in epileptic encephalopathies. Nature 2013; 501:217-221.
2. Brigo F, Storti M. Antiepileptic drugs for the treatment of severe myoclonic epilepsy in infancy. Cochrane Database Syst Rev 2013; 11:CD010483. Systematic evaluation of stiripentol for Dravet, a useful document if data are needed to use stiripentol.
3. Suls A, Jaehn JA, Kecskés A, et al. De novo loss-of-function mutations in CHD2 cause a fever-sensitive myoclonic epileptic encephalopathy sharing features with Dravet syndrome. Am J Hum Genet 2013; 93:967-975.
4. Nava C, Dalle C, Rastetter A, et al. De novo mutations in HCN1 cause early infantile epileptic encephalopathy. Nat Genet 2014; 46:640-645. First demonstration of involvement of mutations in this channel in human epilepsies.
5. Carvill GL,Weckhuysen S, McMahon JM, et al. GABRA1 and STXBP1: novel genetic causes of Dravet syndrome. Neurology 2014; 82:1245-1253. More genes involved in Dravet syndrome.
6. Cherepanova NS, Leslie E, Ferguson PJ, et al. Presence of epilepsy-associated variants in large exome databases. J Neurogenet 2013; 27:1-4.
7. Hirose S, Scheffer IE, Marini C, et al. SCN1A testing for epilepsy: Application in clinical practice. Epilepsia 2013; 54:946-952.
8. Kodera H, Kato M, Nord AS, et al. Targeted capture and sequencing for detection of mutations causing early onset epileptic encephalopathy. Epilepsia 2013; 54:1262-1269.
9. Lemke JR, Riesch E, Scheurenbrand T, et al. Targeted next generation sequencing as a diagnostic tool in epileptic disorders. Epilepsia 2012; 53:1387-1398.
10. Della Mina E, Ciccone R, Brustia F, et al. Improving molecular diagnosis in epilepsy by a dedicated high-throughput sequencing platform. Eur J Hum Genet 2014. [Epub ahead of print]
11. Michaud JL, Lachance M, Hamdan FF, et al. The genetic landscape of infantile spasms. Hum Mol Genet 2014; 23:4846-4858.
12. Helbig I, Swinkels ME, Aten E, et al. Structural genomic variation in childhood epilepsies with complex phenotypes. Eur J Hum Genet 2014; 22:896-901.
13. Lal D, Reinthaler EM, Altmü ller J, et al. RBFOX1 and RBFOX3 mutations in rolandicepilepsy. PLoS One 2013; 8:e73323.
14. Reinthaler EM, Lal D, Lebon S, et al. 16p11.2 600 kb duplications confer risk for typical and atypical Rolandic epilepsy. Hum Mol Genet 2014; 23:6069-6080.
15. Mullen SA, Carvill GL, Bellows S, et al. Copy number variants are frequent in genetic generalized epilepsy with intellectual disability. Neurology 2013; 81:1507-1514.
16. Helbig I, Mefford HC, Sharp AJ, et al. 15q13.3 microdeletions increase risk of idiopathic generalized epilepsy. Nat Genet 2009; 41:160-162.
17. Lowther C, Costain G, Stavropoulos DJ, et al. Delineating the 15q13.3 microdeletion phenotype: A case series and comprehensive review of the literature. Genet Med 2014. [Epub ahead of print]
18. Kobow K, Blümcke I. Epigenetic mechanisms in epilepsy. Prog Brain Res 2014; 213:279-316.
19. Henshall DC. MicroRNA and epilepsy: profiling, functions and potential clinical applications. Curr Opin Neurol 2014; 27:199-205.
20. van Zelst-Stams WA, Scheffer H, Veltman JA. Clinical exome sequencing in daily practice: 1000 patients and beyond. Genome Med 2014; 6:2.
21. Gilissen C, Hehir-Kwa JY, Thung DT, et al. Genome sequencing identifies major causes of severe intellectual disability. Nature 2014; 511:344-347.
22. Farwell KD, Shahmirzadi L, El-Khechen D, et al. Enhanced utility of familycentered diagnostic exome sequencing with inheritance model-based analysis: results from 500 unselected families with undiagnosed genetic conditions. Genet Med 2014. [Epub ahead of print]
23. Martin HC, Kim GE, Pagnamenta AT, et al. Clinical whole-genome sequencing in severe early-onset epilepsy reveals new genes and improves molecular diagnosis. Hum Mol Genet 2014; 23:3200-3211.
24. Ream MA, Mikati MA. Clinical utility of genetic testing in pediatric drugresistant epilepsy: A pilot study. Epilepsy Behav 2014; 37:241-248.
25. Amstutz U, Shear NH, Rieder MJ, et al. Recommendations for HLA-B-15:02 and HLA-A-31:01 genetic testing to reduce the risk of carbamazepineinduced hypersensitivity reactions. Epilepsia 2014; 55:496-506.
26. ChungWH, Chang WC, Lee YS, et al. Genetic variants associated with phenytoinrelated severe cutaneous adverse reactions. JAMA 2014; 312:525-534.
27. Wolking S,Becker F, Bast T, et al. Focal epilepsy in glucose transporter type1 (Glut1) defects: case reports and a review of literature. J Neurol 2014; 261:1881-1886.
28. Ragona F, Matricardi S, Castellotti B, et al. Refractory absence epilepsy and glut1 deficiency syndrome: A new case report and literature review. Neuropediatrics 2014; 45:328-332.
29. Ramm-Pettersen A, Nakken KO, Haavardsholm KC, et al. Occurrence of GLUT1 deficiency syndrome in patients treated with ketogenic diet. Epilepsy Behav 2014; 32:76-78.
30. Hildebrand MS, Damiano JA, Mullen SA, et al. Glucose metabolism transporters and epilepsy: only GLUT1 has an established role. Epilepsia 2014; 55:e18-21.
31. Mills PB, Camuzeaux SS, Footitt EJ, et al. Epilepsy due to PNPO mutations: genotype, environment and treatment affect presentation and outcome. Brain 2014; 137:1350-1360.
32. Baumgart A, Spiczak Sv, Verhoeven-Duif NM, et al. Atypical vitamin B6 deficiency: A rare cause of unexplained neonatal and infantile epilepsies. J Child Neurol 2014; 29:704-707.
33. Al-Baradie RS, Chaudhary MW. Diagnosis and management of cerebral folate deficiency. A form of folinic acid-responsive seizures. Neurosciences (Riyadh) 2014; 19:312-316.
34. Barcia G, Fleming MR, Deligniere A, et al. De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy. Nat Genet 2012; 44:1255-1259.
35. Heron SE, Smith KR, Bahlo M, et al. Missense mutations in the sodium-gated potassium channel gene KCNT1 cause severe autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet 2012; 44:1188-1190.
36. Milligan CJ, Li M, Gazina EV, et al. KCNT1 gain of function in 2 epilepsy phenotypes is reversed by quinidine. Ann Neurol 2014; 75:581-590.
37. Lesca G, Rudolf G, Bruneau N, et al. GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction. Nat Genet 2013; 45:1061-1061.
38. Lemke JR, Lal D, Reinthaler EM, et al. Mutations in GRIN2A cause idiopathic focal epilepsy with rolandic spikes. Nat Genet 2013; 45:1067-1072.
39. Carvill GL, Regan BM, Yendle SC, et al. GRIN2A mutations cause epilepsyaphasia spectrum disorders. Nat Genet 2013; 45:1073-1076.
40. Pierson TM, Yuan H, Marsh ED, et al. GRIN2A mutation and early-onset epileptic encephalopathy: personalized therapy with memantine. Ann Clin-Transl Neurol 2014; 1:190-198.
41. EuroEPINOMICS-RESConsortium;EpilepsyPhenome/GenomeProject;Epi4K Consortium; et al. De novo mutations in synaptic transmission genes including DNM1causeepilepticencephalopathies.AmJHumGenet2014;95:360-370.
42. Lalani SR, Zhang J, Schaaf CP, et al. Mutations in PURA cause profound neonatal hypotonia, seizures, and encephalopathy in 5q31.3 microdeletion syndrome. Am J Hum Genet 2014; 95:579-583.
43. Mignot C, Lambert L, Pasquier L, et al. WWOX-related encephalopathies: delineation of the phenotypical spectrum and emerging genotype-phenotype correlation. J Med Genet 2015; 52:61-70.
44. Thevenon J, Milh M, Feillet F, et al. Mutations in SLC13A5 cause autosomalrecessive epileptic encephalopathy with seizure onset in the first days of life. Am J Hum Genet 2014; 95:113-120.
45. Perrault I, Hamdan FF, Rio M, et al. Mutations in DOCK7 in individuals with epileptic encephalopathy and cortical blindness. Am J Hum Genet 2014; 94:891-897.
46. Basel-Vanagaite L, Hershkovitz T, Heyman E, et al. Biallelic SZT2 mutations cause infantile encephalopathy with epilepsy and dysmorphic corpus callosum. Am J Hum Genet 2013; 93:524-529.
47. Oliver KL, Lukic V, Thorne NP, et al. Harnessing gene expression networks to prioritize candidate epileptic encephalopathygenes. PLoS One 2014; 9:e102079.
48. Hoischen A, Krumm N, Eichler EE. Prioritization of neurodevelopmental disease genes by discovery of new mutations. Nat Neurosci 2014; 17:764-772.
49. Campbell IM, Rao M, Arredondo SD, et al. Fusion of large-scale genomic knowledge and frequency data computationally prioritizes variants in epilepsy. PLoS Genet 2013; 9:e1003797.
50. Ishida S, Picard F, Rudolf G, et al. Mutations of DEPDC5 cause autosomal dominant focal epilepsies. Nat Genet 2013; 45:552-555.
51. Dibbens LM, de Vries B, Donatello S, et al. Mutations in DEPDC5 cause familial focal epilepsy with variable foci. Nat Genet 2013; 45:546-551.
52. Bar-Peled L, Chantranupong L, Cherniack AD, et al. A tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science 2013; 340:1100-1106.
53. Liu J, Reeves C, Michalak Z, et al. Evidence for mTOR pathway activation in a spectrum of epilepsy-associated pathologies. Acta Neuropathol Commun 2014; 2:71.